Načítá se...
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients
OBJECTIVES: A phase I pretargeted radioimmunotherapy trial (EudractCT 200800603096) was designed in patients with metastatic lung cancer expressing carcinoembryonic antigen (CEA) to optimize bispecific antibody and labeled peptide doses, as well as the delay between their injections. METHODS: Three...
Uloženo v:
Vydáno v: | Front Med (Lausanne) |
---|---|
Hlavní autoři: | , , , , , , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
Frontiers Media S.A.
2015
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4661432/ https://ncbi.nlm.nih.gov/pubmed/26640780 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2015.00084 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|